Relevant to CONX/DGX deal today:
Quest Diagnostics Incorporated provides diagnostic testing, information, and services for healthcare industry in the United States. The company offers routine tests, including blood cholesterol level, blood chemistries, complete blood cell counts, pap tests, urinalyses, pregnancy and other prenatal tests, alcohol and other substance-abuse tests, and asthma and allergy tests; esoteric testing services, including gene-based testing; and testing for drugs-of-abuse. It also provides anatomic pathology services, testing for clinical trials, and risk assessment services for the life insurance industry. The company, through its subsidiary, Nichols Institute Diagnostics, manufactures and markets diagnostic test kits and systems primarily for esoteric testing to hospitals, clinical laboratories, and dialysis centers in the United States and internationally. Quest Diagnostics offers a range of clinical laboratory testing services to patients, physicians, hospitals, healthcare insurers, employers, governmental institutions, and other commercial clinical laboratories. The company offers its services through its direct sales force, healthplan sales force, customer service representatives, and couriers. As of December 31, 2006, it operated a network of approximately 2,000 patient service centers and principal laboratories, as well as approximately 150 smaller laboratories. The company was founded in 1967 and is based in Lyndhurst, New Jersey
|
